A Systems Biology Approach to Pharmacogenomic Discovery
|Assistant Professor of Pediatrics, University of Illinois at Chicago, USA|
|*Corresponding Author :||Dr. Wei Zhang
Assistant Professor of Pediatrics
University of Illinois at Chicago
909 South Wolcott Avenue, COMRB Rm.
3099 (MC 719), Chicago, USA
E-mail: [email protected]
|Received November 22, 2011; Accepted November 24, 2011; Published November 28, 2011|
|Citation: Zhang W (2011) A Systems Biology Approach to Pharmacogenomic Discovery. Internal Med: Open Access 1:e102. doi:10.4172/2165-8048.1000e102|
|Copyright: © 2011 Zhang W. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
The individual response to therapeutic treatments is likely to be a complex trait that is controlled by various genetic and non-genetic factors. In an ideal world of personalized medicine, the information about a patient's genetic make-up or gene expression profile would be considered by physicians together with other clinical information (e.g., age, gender) to tailor medical care for both maximizing effective therapy and avoiding adverse effects. The challenge for personalized medicine is particularly urgent for cancer chemotherapy. Clinically, anticancer drugs often present a narrow therapeutic index, indicating that small changes in dosage could cause severe toxic response (e.g., neurotoxicity and nephrotoxicity) [1,2] with the extreme end of complication resulting in fatality. Therefore, understanding the comprehensive relationships between genetic/non-genetic factors and drug response is a critical step toward the realization of personalized medical care in clinical oncology.